ERBB2 and non-small cell lung carcinoma: These results led to the FDA and EMA approval of trastuzumab deruxtecan as the first and only approved targeted therapy for the treatment of metastatic NSCLC with HER2 mutations previously treated with platinum-based chemotherapy.